Patents-Review.com
ClassID:

97204 ⎘

C07K16/3038 - CPC Classification

Classification description:

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells Kidney, bladder

Recent Application in this class:
#1
20260116979
2026-04-30

COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER

 #2
20260049145
2026-02-19

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

 #3
20260028419
2026-01-29

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #4
20260008822
2026-01-08

BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS I-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER

 #5
20250340657
2025-11-06

Methods of Treating IL1RAP Associated Cancers with Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies

 #6
20250333502
2025-10-30

Methods for Manipulating Phagocytosis Mediated by CD47

 #7
20250223367
2025-07-10

FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT

 #8
20250163174
2025-05-22

CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER

 #9
20250154459
2025-05-15

PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS

 #10
20250154282
2025-05-15

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #11
20250129179
2025-04-24

ANTIBODIES BINDING TO HLA-A2/WT1

 #12
20250114392
2025-04-10

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICRENVIRONMENT

 #13
20250114391
2025-04-10

BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT

 #14
20250084185
2025-03-13

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #15
20240425558
2024-12-26

PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS

 #16
20240350528
2024-10-24

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT

 #17
20240309111
2024-09-19

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #18
20240166741
2024-05-23

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

 #19
20240091354
2024-03-21

COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY

 #20
20240084033
2024-03-14

CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO

 #21
20240076404
2024-03-07

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #22
20240043556
2024-02-08

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS

 #23
20240043537
2024-02-08

Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease

 #24
20230293687
2023-09-21

T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF

 #25
20230272100
2023-08-31

ANTIBODIES AGAINST OX-40 AND USES THEREOF

 #26
20230227518
2023-07-20

Peptides for use in immunotherapy against cancers

 #27
20230227517
2023-07-20

NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS

 #28
20230220491
2023-07-13

THERAPEUTIC, DIAGNOSTIC, AND PROGNOSTIC METHODS FOR CANCER

 #29
20230203194
2023-06-29

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #30
20230203146
2023-06-29

ANG2-BINDING MOLECULES

 #31
20230190797
2023-06-22

COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY

 #32
20230151112
2023-05-18

IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE

 #33
20230052212
2023-02-16

FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT

 #34
20230051701
2023-02-16

ANTIBODIES AGAINST CD73 AND USES THEREOF

 #35
20230002450
2023-01-05

Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner

 #36
20220411534
2022-12-29

Antibodies binding to HLA-A2/WT1

 #37
20220324979
2022-10-13

COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER

 #38
20220306766
2022-09-29

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #39
20220267864
2022-08-25

THERAPEUTIC, DIAGNOSTIC, AND PROGNOSTIC METHODS FOR CANCER

 #40
20220267439
2022-08-25

Methods for Manipulating Phagocytosis Mediated by CD47

 #41
20220267384
2022-08-25

PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS

 #42
20220251212
2022-08-11

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

 #43
20220202904
2022-06-30

COMBINED PHARMACEUTICAL COMPOSITION

 #44
20220168395
2022-06-02

COMBINED PHARMACEUTICAL COMPOSITION

 #45
20220144954
2022-05-12

ANTI-VISTA ANTIBODIES AND FRAGMENTS

 #46
20220135635
2022-05-05

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #47
20220119470
2022-04-21

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #48
20220112253
2022-04-14

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #49
20220106396
2022-04-07

Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies and Uses Thereof

 #50
20220064299
2022-03-03

ICOS BINDING PROTEINS

 #51
20220064241
2022-03-03

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #52
20220064240
2022-03-03

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #53
20220054612
2022-02-24

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #54
20220048964
2022-02-17

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #55
20220047620
2022-02-17

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT

 #56
20220040278
2022-02-10

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #57
20220002437
2022-01-06

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #58
20210393756
2021-12-23

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #59
20210371541
2021-12-02

CONJUGATED ANTIBOIDES AGAINST LY75 FOR THE TREATMENT OF CANCER

 #60
20210340253
2021-11-04

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

 #61
20210340203
2021-11-04

Peptides for use in immunotherapy against cancers

 #62
20210340202
2021-11-04

Peptides for use in immunotherapy against cancers

 #63
20210332132
2021-10-28

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

 #64
20210283169
2021-09-16

BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT

 #65
20210277081
2021-09-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #66
20210277073
2021-09-09

KIDNEY DISEASE TARGETS AND USES THEREOF

 #67
20210275652
2021-09-09

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #68
20210238284
2021-08-05

Methods for manipulating phagocytosis mediated by CD47

 #69
20210213116
2021-07-15

CANCER VACCINES FOR KIDNEY CANCER

 #70
20210189004
2021-06-24

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #71
20210179713
2021-06-17

ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF

 #72
20210171640
2021-06-10

Anti-vista antibodies and fragments, uses thereof, and methods of identifying same

 #73
20210155694
2021-05-27

Variant CD3-binding domains and their use in combination therapies for the treatment of disease

 #74
20210095043
2021-04-01

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

 #75
20210079113
2021-03-18

CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO

 #76
20210054067
2021-02-25

ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF

 #77
20210030854
2021-02-04

NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS

 #78
20210009705
2021-01-14

ANTI-OX40 ANTIBODIES AND METHODS OF USE

 #79
20210000951
2021-01-07

COMBINATION THERAPIES

 #80
20200399385
2020-12-24

Antibodies against OX-40 and uses thereof

 #81
20200399366
2020-12-24

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

 #82
20200392249
2020-12-17

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #83
20200392246
2020-12-17

Antibodies to human B7x for treatment of metastatic cancer

 #84
20200339696
2020-10-29

Methods of producing an IL-1 RAP antibodies

 #85
20200325228
2020-10-15

COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER

 #86
20200325194
2020-10-15

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #87
20200291084
2020-09-17

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #88
20200207845
2020-07-02

ANG2-BINDING MOLECULES

 #89
20200197518
2020-06-25

Combination therapy comprising nivolumab and ipilimumab

 #90
20200147190
2020-05-14

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #91
20200140551
2020-05-07

ICOS BINDING PROTEINS

 #92
20200131276
2020-04-30

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

 #93
20200123257
2020-04-23

ICOS binding proteins

 #94
20200102359
2020-04-02

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #95
20200071419
2020-03-05

ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR

 #96
20200048360
2020-02-13

Endoglin Antibodies

 #97
20200017589
2020-01-16

Anti-vista antibodies and fragments

 #98
20190382478
2019-12-19

Nucleolin Antibodies

 #99
20190352359
2019-11-21

Peptides for use in immunotherapy against cancers

 #100
20190336614
2019-11-07

Targeted pyrrolobenzodiazapine conjugates

 #101
20190330355
2019-10-31

Anti-FGFR3 antibodies and methods using same

 #102
20190330350
2019-10-31

ANTI-PD-L1 MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF

 #103
20190328898
2019-10-31

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS

 #104
20190314477
2019-10-17

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #105
20190270826
2019-09-05

ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF

 #106
20190270779
2019-09-05

Re-directed immunotherapy

 #107
20190269770
2019-09-05

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #108
20190263927
2019-08-29

COMBINATION OF A PD-1 ANTAGONIST AND ERIBULIN FOR TREATING UROTHELIAL CANCER

 #109
20190248917
2019-08-15

Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers

 #110
20190248916
2019-08-15

Antibodies binding to HLA-A2/WT1

 #111
20190233515
2019-08-01

Methods for Manipulating Phagocytosis Mediated by CD47

 #112
20190233484
2019-08-01

KIDNEY DISEASE TARGETS AND USES THEREOF

 #113
20190209670
2019-07-11

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #114
20190202924
2019-07-04

Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof

 #115
20190194347
2019-06-27

ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)

 #116
20190185554
2019-06-20

Targeting CLPTM1L for treatment and prevention of cancer

 #117
20190177435
2019-06-13

COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS

 #118
20190177383
2019-06-13

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #119
20190135907
2019-05-09

ANG2-BINDING MOLECULES

 #120
20190117788
2019-04-25

High-affinity anti-human folate receptor beta antibodies and methods of use

 #121
20190106506
2019-04-11

CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER

 #122
20190105406
2019-04-11

Antibody-drug conjugates and immunotoxins

 #123
20190092874
2019-03-28

NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER

 #124
20190092824
2019-03-28

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #125
20190091314
2019-03-28

Peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers

 #126
20190091313
2019-03-28

Peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers

 #127
20190062456
2019-02-28

Antibodies against CD73 and uses thereof

 #128
20190062444
2019-02-28

COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS

 #129
20190062440
2019-02-28

Antigen binding proteins that bind CCR2

 #130
20190060351
2019-02-28

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT

 #131
20190060350
2019-02-28

BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT

 #132
20190048084
2019-02-14

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

 #133
20190010247
2019-01-10

Therapeutic antibodies and uses thereof

 #134
20180369269
2018-12-27

ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN

 #135
20180346572
2018-12-06

Anti-PD-L1 combinations for treating tumors

 #136
20180346538
2018-12-06

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #137
20180344826
2018-12-06

Peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers

 #138
20180334503
2018-11-22

ICOS BINDING PROTEINS

 #139
20180291099
2018-10-11

Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

 #140
20180256693
2018-09-13

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #141
20180251566
2018-09-06

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

 #142
20180251506
2018-09-06

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #143
20180230227
2018-08-16

Anti-OX40 antibodies and methods of use

 #144
20180230205
2018-08-16

Antibodies to endoplasmin and their use

 #145
20180228916
2018-08-16

TARGETED PYRROLOBENZODIAZAPINE CONJUGATES

 #146
20180222973
2018-08-09

Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer

 #147
20180194854
2018-07-12

Endoglin Antibodies

 #148
20180171022
2018-06-21

Monoclonal antibodies

 #149
20180148508
2018-05-31

Masking chimeric antigen receptor T cells for tumor-specific activation

 #150
20180142033
2018-05-24

Cancer therapy using CLDN6 target-directed antibodies in vivo

 #151
20180110875
2018-04-26

Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof

 #152
20180104356
2018-04-19

Methods of treatment for EpCAM positive bladder cancer

 #153
20180104355
2018-04-19

Dosing strategies for targeting EPCAM positive bladder cancer

 #154
20180066032
2018-03-08

NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS

 #155
20180064796
2018-03-08

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #156
20180057602
2018-03-01

COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS

 #157
20180002430
2018-01-04

Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies

 #158
20170327592
2017-11-16

Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor

 #159
20170320945
2017-11-09

Methods for manipulating phagocytosis mediated by CD47

 #160
20170306418
2017-10-26

THERAPEUTIC, DIAGNOSTIC, AND PROGNOSTIC METHODS FOR CANCER

 #161
20170306035
2017-10-26

Antibodies against OX40 and uses thereof

 #162
20170267750
2017-09-21

Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen

 #163
20170253665
2017-09-07

Antibodies against CD73

 #164
20170240638
2017-08-24

Enhancing the therapeutic activity of immune checkpoint inhibitor

 #165
20170233479
2017-08-17

Method of identifying anti-VISTA antibodies

 #166
20170224837
2017-08-10

COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS

 #167
20170224836
2017-08-10

Anti-CDH6 antibody drug conjugates

 #168
20170209574
2017-07-27

COMBINATION THERAPIES

 #169
20170204188
2017-07-20

Anti-FGFR3 antibodies and methods using same

 #170
20170174773
2017-06-22

Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer

 #171
20170166653
2017-06-15

Antibodies for epidermal growth factor receptor 3 (HER3)

 #172
20170166641
2017-06-15

Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer

 #173
20170145102
2017-05-25

FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

 #174
20170143846
2017-05-25

TARGETED PYRROLOBENZODIAZAPINE CONJUGATES

 #175
20170143827
2017-05-25

Compositions comprising a combination of nivolumab and ipilimumab

 #176
20170121420
2017-05-04

ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF

 #177
20170114137
2017-04-27

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

 #178
20170112894
2017-04-27

Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment

 #179
20170107284
2017-04-20

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS

 #180
20170107281
2017-04-20

ANG2-BINDING MOLECULES

 #181
20170106095
2017-04-20

ANTIBODY DRUG CONJUGATES

 #182
20170101464
2017-04-13

Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

 #183
20170100425
2017-04-13

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

 #184
20170100424
2017-04-13

β-glucan methods and compositions that affect the tumor microenvironment

 #185
20170088627
2017-03-30

Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist

 #186
20170051067
2017-02-23

Antibodies which bind to the human CC chemokine receptor 4 and uses thereof

 #187
20170051061
2017-02-23

Anti-vista antibodies and fragments

 #188
20170044267
2017-02-16

Endoglin antibodies

 #189
20170044262
2017-02-16

Humanized monoclonal antibodies and methods of use

 #190
20170044259
2017-02-16

Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof

 #191
20170044256
2017-02-16

Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors

 #192
20170037146
2017-02-09

Mutated antibody of fully humanized HER2 antibody, and encoding gene and use thereof

 #193
20170037127
2017-02-09

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

 #194
20170037110
2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #195
20170037107
2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #196
20170037098
2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #197
20170037097
2017-02-09

Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers

 #198
20170037096
2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #199
20170037095
2017-02-09

Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide

 #200
20170037094
2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #201
20170037093
2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #202
20170037092
2017-02-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #203
20170035906
2017-02-09

(Anti-HER2 antibody)-drug conjugate

 #204
20170029525
2017-02-02

ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER

 #205
20170029516
2017-02-02

Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof

 #206
20170029505
2017-02-02

MULTIMERIC FC PROTEINS

 #207
20170028080
2017-02-02

Targeted Drug Conjugates

 #208
20170022287
2017-01-26

Immunoactivating antigen-binding molecule

 #209
20170022273
2017-01-26

Antibody therapeutics that bind LAG3

 #210
20170015755
2017-01-19

COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS

 #211
20170008976
2017-01-12

Anti-metalloprotease antibody for diagnosis and treatment of cancers

 #212
20170008971
2017-01-12

METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES

 #213
20170007716
2017-01-12

Antibody-drug conjugates and immunotoxins

 #214
20170002046
2017-01-05

PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS

 #215
20160376328
2016-12-29

PROTEINS COMPRISING AMINO-TERMINAL PROXIMAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND CELL-TARGETING IMMUNOGLOBULIN-TYPE BINDING REGIONS

 #216
20160369003
2016-12-22

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

 #217
20160362494
2016-12-15

ICOS binding proteins

 #218
20160362461
2016-12-15

KIDNEY DISEASE TARGETS AND USES THEREOF

 #219
20160355604
2016-12-08

Cancer therapy using CLDN6 target-directed antibodies in vivo

 #220
20160347855
2016-12-01

PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF

 #221
20160347849
2016-12-01

Antibodies against OX40 and uses thereof

 #222
20160347848
2016-12-01

THERAPEUTIC COMBINATIONS AND METHODS FOR TREATING NEOPLASIA

 #223
20160334407
2016-11-17

Anti-Uroplakin II antibodies systems and methods

 #224
20160333110
2016-11-17

Anti-human TROP-2 antibody having an antitumor activity in vivo

 #225
20160333083
2016-11-17

Targeting CLPTM1L for treatment and prevention of cancer

 #226
20160326245
2016-11-10

Frizzled receptor antibodies for treatment of cancer

 #227
20160311916
2016-10-27

Anti-CD40 antibodies

 #228
20160304607
2016-10-20

COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY

 #229
20160304605
2016-10-20

Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

 #230
20160297889
2016-10-13

Pharmaceutical composition for treatment and/or prevention of cancer

 #231
20160289329
2016-10-06

Antigen binding proteins that bind CCR2

 #232
20160289296
2016-10-06

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #233
20160287687
2016-10-06

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

 #234
20160280794
2016-09-29

Compositions and methods relating to universal glycoforms for enhanced antibody efficacy

 #235
20160272730
2016-09-22

Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides

 #236
20160272719
2016-09-22

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

 #237
20160272712
2016-09-22

Anti-PD-L1 monoclonal antibodies and fragments thereof

 #238
20160263243
2016-09-15

Antibody drug conjugates (ADC) that bind to 191P4D12 proteins

 #239
20160257760
2016-09-08

Conjugated antibodies against LY75 for the treatment of cancer

 #240
20160257752
2016-09-08

Methods of treating cancers using PD-1 axis binding antagonists and taxanes

 #241
20160256563
2016-09-08

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS

 #242
20160215059
2016-07-28

ICOS binding proteins

 #243
20160215050
2016-07-28

Nucleolin antibodies

 #244
20160207990
2016-07-21

Antibodies to endoplasmin and their use

 #245
20160200816
2016-07-14

Methods of manipulating phagocytosis mediated by CD47

 #246
20160194405
2016-07-07

ANTI-TISSUE FACTOR ANTIBODIES AND COMPOSITIONS

 #247
20160184399
2016-06-30

COMBINED PHARMACEUTICAL COMPOSITION

 #248
20160176985
2016-06-23

Humanized monoclonal antibodies and methods of use

 #249
20160176978
2016-06-23

Methods of manipulating phagocytosis mediated by CD47

 #250
20160176977
2016-06-23

NOVEL ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER

 #251
20160176976
2016-06-23

Methods of manipulating phagocytosis mediated by CD47

 #252
20160175437
2016-06-23

PROTEIN

 #253
20160145355
2016-05-26

BISPECIFIC ANTIBODIES

 #254
20160145350
2016-05-26

Antibodies against CD73

 #255
20160130299
2016-05-12

Tubulysin analogs and methods of making and use

 #256
20160102151
2016-04-14

Compositions and methods for treatment and detection of cancers

 #257
20160031985
2016-02-04

CHARGE-ENGINEERED ANTIBODIES OR COMPOSITIONS OF PENETRATION-ENHANCED TARGETING PROTEINS AND METHODS OF USE

 #258
20160009815
2016-01-14

Methods for manipulating phagocytosis mediated by CD47

 #259
20160009814
2016-01-14

Methods for manipulating phagocytosis mediated by CD47

 #260
20150307617
2015-10-29

Anti-OX40 antibodies and methods of use

 #261
20150274839
2015-10-01

Antibodies to non-functional P2X7 receptor

 #262
20150274837
2015-10-01

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

 #263
20150247861
2015-09-03

Anti-uroplakin II antibodies systems and methods

 #264
20150216970
2015-08-06

Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

 #265
20150210770
2015-07-30

THERAPEUTIC AND DIAGNOSTIC TARGET

 #266
20150209427
2015-07-30

Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

 #267
20150147278
2015-05-28

Antibody against transporter and use thereof

 #268
20140295462
2014-10-02

RBM3 protein in colorectal cancer prognostics

 #269
20140220005
2014-08-07

N-cadherin: target for cancer diagnosis and therapy

 #270
20140194601
2014-07-10

Antibody drug conjugates (ADC) that bind to 161P2F10B proteins

 #271
20140170676
2014-06-19

RBM3 in bladder cancer

 #272
20140140990
2014-05-22

Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

 #273
20140079628
2014-03-20

Anti-tissue factor antibodies and compositions

 #274
20140051096
2014-02-20

NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS

 #275
20130230584
2013-09-05

Treating bladder tumor cells using fibronectin attachment protein as a target

 #276
20130183305
2013-07-18

Cancer therapy using CLDN6 target-directed antibodies in vivo

 #277
20130164216
2013-06-27

Bladder cancer tumor marker, antibody and use thereof

 #278
20130052667
2013-02-28

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

 #279
20130046078
2013-02-21

Anti-FGFR3 antibodies and methods using same

 #280
20130028919
2013-01-31

Targeted pyrrolobenzodiazapine conjugates

 #281
20120321606
2012-12-20

CRYSTAL STRUCTURES AND METHODS USING SAME

 #282
20120294864
2012-11-22

Endoglin antibodies

 #283
20120183552
2012-07-19

KIDNEY DISEASE TARGETS AND USES THEREOF

 #284
20120107306
2012-05-03

Antibodies for epidermal growth factor receptor 3 (HER3)

 #285
20120093819
2012-04-19

Antibodies that specifically block the biological activity of kidney associated antigen 1 (KAAG1)

 #286
20120078028
2012-03-29

Antibody drug conjugates (ADC) that bind to 191P4D12 proteins

 #287
20120063999
2012-03-15

PSCA: prostate stem cell antigen and uses thereof

 #288
20120059151
2012-03-08

Non-functional P2Xreceptor

 #289
20120058131
2012-03-08

PTA089 PROTEIN

 #290
20120040338
2012-02-16

RBM3 in Testicular Cancer Diagnostics and Prognostics

 #291
20120034218
2012-02-09

RBM3 in colorectal cancer prognostics

 #292
20120029172
2012-02-02

Humanized GM-CSF antibodies

 #293
20120009194
2012-01-12

Antibodies to endoplasmin and their use

 #294
20110311450
2011-12-22

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS

 #295
20110293609
2011-12-01

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

 #296
20110287016
2011-11-24

Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer

 #297
20110223107
2011-09-15

Anti-kidney associated antigen 1 (KAAG1) antibodies

 #298
20110217321
2011-09-08

Antibody drug conjugates (ADC) that bind to 161P2F10B proteins

 #299
20110171210
2011-07-14

Humanized monoclonal antibodies and methods of use

 #300
20110092674
2011-04-21

Non-functional P2Xreceptor